Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
11 October 2018 | Story UFS | Photo Zama Feni
UFS launch student business incubator project
Rector and Vice-Chancellor Francis Peterson cutting the ribbon as the office of Student Business Incubator Project was officially opened last Friday.
The University of Free State has recently launched a Student Business Incubator Project that will provide impetus to students with business ideas.

The initiative, which is under the management of the Directorate for Research and Development (DRD) was conceived a few years ago with objective of untapping the entrepreneurial potential of students. 

And it was on Friday last week that all the energy and efforts that were directed towards the planning of this project culminated into the official launch and opening of the offices where the students will conduct their business operations.

Generate new business ideas

Delivering a brief address at the launch, Rector and Vice-Chancellor, Prof Francis Petersen encouraged students to generate new business ideas that would make them job creators at the end of the day. 

“As a university, we should disseminate our output to society through research, education and technology transfer. The Incubator Project is a good initiative and I would like to see it growing so that more students can benefit from a facility such as this,” he said. 
Professor Petersen encouraged the student innovators to engage society so that they can make quality of life better through new knowledge.

“You must continue to incubate ideas and develop them,” he said adding that one of the great things that a university is measured about is the employability of its graduates.

Business ideas awarded 
On the previous day, DRD hosted a pitching competition for the business ideas that students were invited to submit.

Assistant Research Officer and Project Manager, Ayanda Makhanya said they were excited about the outcome of their call to students as they received an overall total of 60 ideas.

“We screened all the inputs and came up with 14 ideas. We will now be working with these students to provide the necessary support,” she said.

The winner in the pitching competition was an LLB student Mannini Setai whose idea was the production of eco-friendly bricks.

The office are located near the UFS Sasol Library and has computers and a big flat screen.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept